2015 Antibiotic Susceptibility Report

Size: px
Start display at page:

Download "2015 Antibiotic Susceptibility Report"

Transcription

1 Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens Stenotrophomonas Fairview Lakes Medical Center 2015 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2015 Gram-Negative Non-Urine The number of isolates is listed along with the percent of susceptible strains. No. Isolates Amikacin Amoxicillin/Clav (Augmentin) IR IR IR 95 IR IR Ampicillin IR IR IR IR IR 82 IR IR Ampicillin/Sulbactam (Unasyn) IR IR IR IR IR Aztreonam * Cefazolin IR IR IR IR IR Cefepime Cefoxitin IR IR IR NT NT NT NT IR IR Ceftazidime - 3rd Generation Ceftriaxone - 3rd Generation IR 96 Ciprofloxacin Gentamicin Levofloxacin Meropenem (Merrem) Piperacillin/Tazo (Zosyn) Ticarcillin/Clav (Timentin) * 25 Tobramycin Trimethoprim/Sulfa (Bactrim) IR NT 97 : Cumulative data for Stenotrophomonas maltophilia is intrinsically resistant to tetracycline, but not to doxycycline, minocycline, or tigecycline. Enterobactoer and Serratia may develop resistance during prolonged therapy with 3rd generation cephalosporins. Isolates that are initially susceptible may become resistant within 3-4 days.. Enterobacteriaceae are intrinsically resistant to clindamycin, daptomycin, fusidic acid, glycopeptides (vancomycin, teicoplanin), linezolid, quinupristin-dalfopristin, rifampin, and macrolides (erythromycin, clarithromycin, and azithromycin). However, there are some exceptions with macrolides (ie, Salmonella and Shigella spp. with azithromycin) Page 1 of 5

2 Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Klebsiella oxytoca Klebsiella pneumoniae Morganella morganii Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens Stenotrophomonas GRAM-NEGATIVE ORGANISMS 2015 Gram-Negative Urine The number of isolates is listed along with the percent of susceptible strains. No. Isolates Amikacin * * * * * * * * * * *NT Ampicillin IR IR IR 65 IR IR IR 90 IR IR Ampicillin/Sulbactam (Unasyn) IR IR IR NT 94 IR IR Cefazolin IR IR IR IR 95 IR IR Cefepime *NT Cefoxitin IR IR IR NT IR Ceftazidime - 3rd Generation *NT Ceftriaxone - 3rd Generation IR 96 Ciprofloxacin Gentamicin Levofloxacin 96 *NT *NT *NT Meropenem (Merrem) * * * * * * * * 100 * Nitrofurantoin (Macrobid) IR IR NT IR Piperacillin/Tazo (Zosyn) * Tobramycin Trimethoprim/Sulfa (Bactrim) NT IR *NT 84 : Cumulative data for Cefazolin results predict results for the oral agents cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil, cephalexin, and loracarbef when used for therapy of uncomplicated UTIs due to E.coli, K. pneumoniae, and P. mirabilis. Stenotrophomonas maltophilia is intrinsically resistant to tetracycline, but not to doxycycline, minocycline, or tigecycline. Enterobacter and Serratia may develop resistance during prolonged therapy with 3rd generation cephalosporins. Isolates that are initially susceptible may become resistant within 3-4 days. Enterobacteriaceae are intrinsically resistant to clindamycin, daptomycin, fusidic acid, glycopeptides (vancomycin, teicoplanin), linezolid, quinupristin-dalfopristin, rifampin, and macrolides (erythromycin, clarithromycin, and azithromycin). However, there are some exceptions with macrolides (ie, Salmonella and Shigella spp. with azithromycin) Page 2 of 5

3 Enterococcus Species (Group D. Enterococcus) Staph. Aureus, MSSA Staph. Aureus, MRSA Coag. Negative Staph Strep Agalactiae Group B GRAM-POSITIVE ORGANISMS 2015 Gram- Positive Non-Urine The number of isolates is listed along with the percent of susceptible strains. Staph. lugdunensis Strep. Pneumonia Beta-hemolytic Strep (Groups A, C, F, G) No. Isolates Ampicillin 100 NT NT NT NT NT Cefotaxime - 3rd Generation IR NT NT NT NT NT Ceftriaxone - 3rd Generation IR NT NT NT NT Ceftriaxone (mening) 88 Ceftriaxone (nonmen) 96 Ciprofloxacin NT NT NT Meropenem (Merrom) 94 Clindamycin IR Erythromycin IR NT Gentamicin NT NT NT Levofloxacin NT Linezolid NT NT NT Oxacillin NT NT NT NT Penicillin Penicillin (mening) 68 Penicillin (nonmen) 93 Quinupristin / Dalfoprisin (Synercid) NT NT NT Tetracycline NT NT NT Trimethoprim/Sulfa (Bactrim) IR NT NT NT Vancomycin : Cumulative data for : Synercid used for Vancomycin Resistant Enterococcus faecium only intrinsic resistance shown with other Enterococcus species Page 3 of 5

4 Enterococcus faecalis Enterococcus faecium Staph. Aureus, MSSA Staph. Aureus, MRSA Coag. Negative Staph Strep Agalactiae Group B Aerococcus Urinae GRAM-POSITIVE ORGANISMS 2015 Gram-Positive Urine The number of isolates is listed along with the percent of susceptible strains. No. Isolates Ampicillin NT NT NT Ciprofloxacin NT Clindamycin IR IR NT NT NT * Erythromycin IR IR NT NT NT * Rifampicin * NT NT * * * NT Quinupristin / Dalfoprisin (Synercid) * IR NT NT NT NT Moxifloxacin * * * * * NT NT Gentamicin NT Levofloxacin Linezolid * * 100 * * * * Nitrofurantoin (Macrobid) NT Oxacillin NT NT NT Penicillin Tetracycline NT Trimethoprim/Sulfa (Bactrim) IR IR NT NT IR Vancomycin : Cumulative data for : Synercid used for Vancomycin Resistant Enterococcus faecium only intrinsic resistance shown with other Enterococcus species STAPHYLOCOCCUS: PENICILLINASE-LABILE PENICILLINS Penicillin-susceptible staphylococci are also susceptible to other ß-lactam agents with established clinical efficacy for staphylococcal infections. Penicillin-resistant staphylococci are resistant to penicillinase-labile penicillins, including ampicillin, amoxicillin, azlocillin, carbenicillin, mezlocillin, piperacillin, and tiarcillin. PENICILLINASE-STABLE PENICILLINS Oxacillin results can be applied to the other penicillinase-stable penicillins (cloxacillin, dicloxacillin, flucloxacillin, methicillin, and nafcillin). For agents with established clinical efficacy and considering site of infection and appropriate dosing, oxacillin susceptible staphylococci can be considered susceptible to: ß-lactam/ß-lactamase inhibitor combinations (amoxicillin-clavulanate, ampicillin-sulbactam, piperacillin-tazobactam, ticarcillinclavulanate) Oral cephems (cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime, loracarbef) Parenteral cephems including cephalosporins I, II, III, and IV (cefamandole, cefazolin, cefepime, cefmatazole, cefonicid, cefoperazone, cefotaxime, cefotetan, ceftizoxime, ceftriaxone, cefuroxime, cephalothin, ceftaroline, moxalactam) Carbapenems (doripenem, ertapenem, imipenem, meropenem) Page 4 of 5

5 Oxacillin-resistant staphylococci are resistant to all currently available B-lactam antimicrobial agents, with the exception of the newer cephalosporins with anti-mrsa activity. Thus, susceptibility or resistance to a wide array of B-lactam antimicrobial agents may be deduced from testing only penicillin and oxacillin. Routine testing of other B-lactam agents, except those with anti-mrsa activity, is not advised. ENTEROCOCCUS: The results of ampicillin susceptibility tests should be used to predict the activity of amoxicillin. Ampicillin results may be used to predict susceptibility to amoxicillin clavulanate, ampicillin-sulbactam, pipercillin, and piperacillin-tazobactam among non-b-lactamase producing enterococci. Ampicillin susceptibility can be used to predict imipenem susceptibility, providing the species is confirmed to be E. faecalis. Enterococci susceptible to penicillin are predictably susceptible to ampicillin, amoxicillin, ampicillin-sulbactam, amoxicillin-clavulanate, pipercillin and piperacillin-tazobactam for non-b-lactamase-producing entercocci. However, enterococci susceptible to ampicillin cannot be assumed to be susceptible to penicillin. If penicillin results are needed, testing of penicillin is required. FLUOROQUINOLONES Enterococcus spp. and Staphylococcus spp. May develop resistance during prolonged therapy with quinolones. Therefore, isolates that are initially susceptible may become resistant within three to four days after initiation of therapy. Testing of repeat isolates may be warranted. TETRACYCLINES that are susceptible to tetracycline are also considered susceptible to doxycycline and minocycline. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxcycline, minocycline, or both. Reviewed: Helen Brenny, Director of Laboratory Operations 5/2016 Page 5 of 5

2016 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates

More information

January 2014 Vol. 34 No. 1

January 2014 Vol. 34 No. 1 January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton

More information

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016 Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate

More information

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine 2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

56 Clinical and Laboratory Standards Institute. All rights reserved.

56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:

More information

Antimicrobial Susceptibility Testing: Advanced Course

Antimicrobial Susceptibility Testing: Advanced Course Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to

More information

EUCAST recommended strains for internal quality control

EUCAST recommended strains for internal quality control EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC

More information

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه

More information

Routine internal quality control as recommended by EUCAST Version 3.1, valid from

Routine internal quality control as recommended by EUCAST Version 3.1, valid from Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.

More information

Antimicrobial Susceptibility Testing: The Basics

Antimicrobial Susceptibility Testing: The Basics Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories

More information

January 2014 Vol. 34 No. 1

January 2014 Vol. 34 No. 1 January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton

More information

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory

More information

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria

More information

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services 2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The

More information

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

RCH antibiotic susceptibility data

RCH antibiotic susceptibility data RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological

More information

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015 Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New

More information

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance

More information

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014

More information

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are

More information

Intrinsic, implied and default resistance

Intrinsic, implied and default resistance Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and

More information

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital 2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram

More information

Antimicrobial susceptibility

Antimicrobial susceptibility Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007

More information

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital 2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....

More information

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance

More information

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to

More information

What s new in EUCAST methods?

What s new in EUCAST methods? What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests

More information

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

Compliance of manufacturers of AST materials and devices with EUCAST guidelines Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The

More information

Antibiotic Stewardship Program (ASP) CHRISTUS SETX

Antibiotic Stewardship Program (ASP) CHRISTUS SETX Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:

More information

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2. AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony

More information

This document is protected by international copyright laws.

This document is protected by international copyright laws. Table 2C Table 2C. and s for Product Name: Infobase 2010 - Release Date: February 2010 60 Clinical and Laboratory Standards Institute. All rights reserved. Testing Conditions Medium: diffusion: MHA Broth

More information

C&W Three-Year Cumulative Antibiogram January 2013 December 2015

C&W Three-Year Cumulative Antibiogram January 2013 December 2015 C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...

More information

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

Compliance of manufacturers of AST materials and devices with EUCAST guidelines Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The

More information

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be

More information

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review (1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of

More information

Cell Wall Weakeners. Antimicrobials: Drugs that Weaken the Cell Wall. Bacterial Cell Wall. Bacterial Resistance to PCNs. PCN Classification

Cell Wall Weakeners. Antimicrobials: Drugs that Weaken the Cell Wall. Bacterial Cell Wall. Bacterial Resistance to PCNs. PCN Classification Cell Wall Weakeners Antimicrobials: Drugs that Weaken the Cell Wall Beta Lactams Penicillins Cephalosporins Carbapenems Aztreonam Vancomycin Teicoplanin Bacterial Cell Wall Bacterial cytoplasm is hypertonic

More information

GENERAL NOTES: 2016 site of infection type of organism location of the patient

GENERAL NOTES: 2016 site of infection type of organism location of the patient GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered

More information

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California

More information

microbiology testing services

microbiology testing services microbiology testing services You already know Spectra Laboratories for a wide array of dialysis-related testing services. Now get to know us for your microbiology needs. As the leading provider of renal-specific

More information

Performance Information. Vet use only

Performance Information. Vet use only Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.

More information

Antimicrobial Susceptibility Patterns

Antimicrobial Susceptibility Patterns Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department

More information

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How

More information

British Society for Antimicrobial Chemotherapy

British Society for Antimicrobial Chemotherapy British Society for Antimicrobial Chemotherapy BSAC to actively support the EUCAST Disc Diffusion Method for Antimicrobial Susceptibility Testing in preference to the current BSAC Disc Diffusion Method

More information

QUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)

QUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Pseudomonas aeruginosa (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Description: Greenish gray colonies with some beta-hemolysis around each colony on blood agar (BAP),

More information

Advanced Practice Education Associates. Antibiotics

Advanced Practice Education Associates. Antibiotics Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright

More information

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical

More information

British Society for Antimicrobial Chemotherapy

British Society for Antimicrobial Chemotherapy British Society for Antimicrobial Chemotherapy Standing Committee on Susceptibility Testing Version 13.0, 10-06-2014 Content Page Additional information Changes in version 13 2 Suggestions for appropriate

More information

Principles of Antibiotics Use & Spectrum of Some

Principles of Antibiotics Use & Spectrum of Some Principles of Antibiotics Use & Spectrum of Some Rabee Adwan. MD Infectious Diseases Consultant (Pediatric and Adult) Head Of ID Unit and IPAC Committee- AL-Makassed Hospital-AlQuds Head of IPAC Committee

More information

AMR Industry Alliance Antibiotic Discharge Targets

AMR Industry Alliance Antibiotic Discharge Targets AMR Industry Alliance Antibiotic Discharge Targets List of Predicted No-Effect Concentrations (PNECs) The members of the AMR Industry Alliance have developed a unified approach to establishing discharge

More information

Antibiotic Updates: Part II

Antibiotic Updates: Part II Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

Antimicrobial Susceptibility Summary 2011

Antimicrobial Susceptibility Summary 2011 Antimicrobial Susceptibility Summary 2011 Clinical Microbiology Department of Pathology & Laboratory Medicine 45 Antimicrobial Susceptibility Summary Clinical Microbiology Department of Pathology and Laboratory

More information

Leveraging the Lab and Microbiology Department to Optimize Stewardship

Leveraging the Lab and Microbiology Department to Optimize Stewardship Leveraging the Lab and Microbiology Department to Optimize Stewardship Presented by: Andrew Martinez MLS(ASCP), MT(AMT), MBA Alaska Native Medical Center Microbiology Supervisor Maniilaq Health Center

More information

TABLE OF CONTENTS. Urine - Gram Positive Susceptibility Reporting 1 Staphylococcus species, MRSA...11

TABLE OF CONTENTS. Urine - Gram Positive Susceptibility Reporting 1 Staphylococcus species, MRSA...11 Policy #MI\ANTI\v23 Page 1 of 3 Section: Antimicrobial Susceptibility Testing Subject Title: Table of Contents Manual Issued by: LABORATORY MANAGER Original Date: January 10, 2000 Approved by: Laboratory

More information

Approach to pediatric Antibiotics

Approach to pediatric Antibiotics Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus

More information

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018 Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?

More information

York Chairman David B. Jones, MD

York Chairman David B. Jones, MD York Chairman David B. Jones, MD Pathologists Abby W. Davis, MD David A. Derrick, MD J. Ander Pindzola, MD John A. Wright, MD Stanley D. Hurtt, MD Matthew F. Georgy, MD Michelle L. Erickson, MD, MBA William

More information

Understanding the Hospital Antibiogram

Understanding the Hospital Antibiogram Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital

More information

EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia

EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia Background The Expert Advisory Group on Antimicrobial Resistance of the NH&MRC provides advice to Australian governments and

More information

Antimicrobial Resistance Advisory Workgroup (ARAW) Members

Antimicrobial Resistance Advisory Workgroup (ARAW) Members Antimicrobial Resistance Advisory Workgroup (ARAW) Members Jackie Aguilar, BSN, RN Anne Diefendorf, MS, RD Ella Martin, MD Lisa Tibbitts, RN, BSN, MSNed, BC Bobbie Bagley, RN, MS, MCH, CPH Apara Dave,

More information

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical

More information

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds

More information

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient 1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime

More information

دکتر فرينبز راشذ مرنذی متخصص آسيب شنبسی تشريحی و ببلينی عضو هيئت علمی آزمبيشگبه مرجع سالمت

دکتر فرينبز راشذ مرنذی متخصص آسيب شنبسی تشريحی و ببلينی عضو هيئت علمی آزمبيشگبه مرجع سالمت دکتر فرينبز راشذ مرنذی متخصص آسيب شنبسی تشريحی و ببلينی عضو هيئت علمی آزمبيشگبه مرجع سالمت Antibiotical grouping Mechanisms of action Bacteriostatic Bacteriocidal Site of action Antibiotics Antibiotics

More information

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis

More information

CUMULATIVE ANTIBIOGRAM

CUMULATIVE ANTIBIOGRAM BC Children s Hospital and BC Women s Hospital & Health Centre CUMULATIVE ANTIBIOGRAM 2017 Division of Medical Microbiology Department of Pathology and Laboratory Medicine Page 1 of 5 GRAM-POSITIVE BACTERIA

More information

Antimicrobial Susceptibility Summary 2012

Antimicrobial Susceptibility Summary 2012 Antimicrobial Susceptibility Summary 2012 Clinical Microbiology Department of Pathology & Laboratory Medicine 46 53 Antimicrobial Susceptibility Summary Clinical Microbiology Department of Pathology and

More information

BSAC standardized disc susceptibility testing method (version 8)

BSAC standardized disc susceptibility testing method (version 8) Journal of Antimicrobial Chemotherapy (2009) 64, 454 489 doi:10.1093/jac/dkp244 Advance Access publication 8 July 2009 BSAC standardized disc susceptibility testing method (version 8) J. M. Andrews* for

More information

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,

More information

BactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21

BactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21 www.wslhpt.org 2601 Agriculture Drive Madison, WI 53718 (800) 462-5261 (608) 265-1111 2015-BactiR Reg3 Shipment Date: September 14, 2015 Questions or comments should be directed to Amanda Weiss at 800-462-5261

More information

SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...

SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ... SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* The next-generation MicroScan WalkAway System combines proven technology and reliability with enhanced ease-of-use features to streamline

More information

ß-lactams. Sub-families. Penicillins. Cephalosporins. Monobactams. Carbapenems

ß-lactams. Sub-families. Penicillins. Cephalosporins. Monobactams. Carbapenems β-lactams ß-lactams Sub-families Penicillins Cephalosporins Monobactams Carbapenems ß-lactams Mode of action PBPs = Trans/Carboxy/Endo- peptidases PBP binding (Penicillin-Binding Proteins) activation of

More information

Penicillins - EUCAST clinical MIC breakpoints (version 1.3)

Penicillins - EUCAST clinical MIC breakpoints (version 1.3) EUCAST clinical MIC breakpoints - penicillins Penicillins - EUCAST clinical MIC breakpoints 2009-04-19 (version 1.3) Penicillins Click on antibiotic name to see wild type MIC distributions. Enterobacteriaceae

More information

Medicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!

Medicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck! Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which

More information

Preserve the Power of Antibiotics

Preserve the Power of Antibiotics PROVIDERInsight News for providers in Northeast Nebraska April 2016 Preserve the Power of Antibiotics Antimicrobial stewardship interventions have been proven to improve individual patient outcomes, reduce

More information

Recommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data

Recommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data Recommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data Trevor Van Schooneveld MD, Scott Bergman, PharmD, BCPS, Paul Fey, PhD, Mark Rupp, MD The Clinical Microbiology laboratory

More information

Antimicrobial Therapy

Antimicrobial Therapy Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the

More information

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information

More information

The Very Latest from the CLSI AST Subcommittee.

The Very Latest from the CLSI AST Subcommittee. 2 0 1 4 The Very Latest from the CLSI AST Subcommittee. Susan E. Sharp, Ph.D., DABMM, FAAM Director - Regional Laboratory Director - Regional Microbiology/Molecular Infectious Diseases Diagnostics Laboratory

More information

Evaluation of the BIOGRAM Antimicrobial Susceptibility Test System

Evaluation of the BIOGRAM Antimicrobial Susceptibility Test System JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1985, p. 793-798 0095-1137/85/110793-06$02.00/0 Copyright 1985, American Society for Microbiology Vol. 22, No. 5 Evaluation of the BIOGRAM Antimicrobial Susceptibility

More information

Antimicrobial Resistance Trends in the Province of British Columbia

Antimicrobial Resistance Trends in the Province of British Columbia 655 West 12th Avenue Vancouver, BC V5Z 4R4 Tel 604.707.2443 Fax 604.707.2441 www.bccdc.ca Antimicrobial Resistance Trends in the Province of British Columbia 2013 Prepared by the Do Bugs Need Drugs? Program

More information

Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes

Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes Prof C. Wattal Hon. Sr. Consultant & Chairman Dept. of Clinical Microbiology Sir Ganga Ram Hospital New Delhi

More information

4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases

4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases 4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome

More information

Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland,

Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland, Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland, 2008-2016 Alicia Russell Federation of Infection Societies conference 14 th November 2018 alisia_russell BSAC

More information

Antimicrobials. Antimicrobials

Antimicrobials. Antimicrobials Antimicrobials For more than 50 years, antibiotics have come to the rescue by routinely producing rapid and long-lasting miracle cures. However, from the beginning antibiotics have selected for resistance

More information

2015 Antimicrobial Susceptibility Report

2015 Antimicrobial Susceptibility Report Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf

More information

Infectious Disease: Drug Resistance Pattern in New Mexico

Infectious Disease: Drug Resistance Pattern in New Mexico Infectious Disease: Drug Resistance Pattern in New Mexico Are these the world's sexiest accents? Obi C. Okoli, MD.,MPH. Clinic for Infectious Diseases Las Cruces, NM. Are these the world's sexiest accents?

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #116 (NQF 0058): Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY

More information

Principles of Infectious Disease. Dr. Ezra Levy CSUHS PA Program

Principles of Infectious Disease. Dr. Ezra Levy CSUHS PA Program Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,

More information

5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)

5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO) Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health

More information

Antibacterial Resistance In Wales

Antibacterial Resistance In Wales A Report from Public Health Wales Antimicrobial Resistance Programme Surveillance Unit: Antibacterial Resistance In Wales 2005-2012 Authors: Maggie Heginbothom Robin Howe & Catherine Thomas Version: 1

More information

Mongolia September 2012

Mongolia September 2012 MICROBIOLOGY: bacterial resistance Roßburg / 9.9.22 MVZ DORTMUND - Dr.Eberhard u. Partner - MICROBIOLOGY bacterial resistance control, role of the laboratory MIKROBIOLOGY www.labmed.de / mikro@labmed.de

More information

Update on the CLSI Standards for Antimicrobial Susceptibility Testing: What s New with the Gram Positive Organisms?

Update on the CLSI Standards for Antimicrobial Susceptibility Testing: What s New with the Gram Positive Organisms? 2 0 1 3 CASES (with answers!) Update on the CLSI Standards for Antimicrobial Susceptibility Testing: What s New with the Gram Positive Organisms? Susan E. Sharp, Ph.D., DABMM, FAAM Director - Regional

More information

Solution Title: Antibiotic Stewardship: A Journey Toward the Triple Aim

Solution Title: Antibiotic Stewardship: A Journey Toward the Triple Aim Solution Title: Antibiotic Stewardship: A Journey Toward the Triple Aim Program/Project Description, including Goals What was the problem to be solved? How was it identified? What baseline data existed?

More information